| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCCA1/SCCA2 |
| Uniprot No | P29508 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-390aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMNSLSEANTKFMFDLFQQFRKSKENNI FYSPISITSALGMVLLGAKDNTAQQIKKVLHFDQVTENTTGKAATYHVDR SGNVHHQFQKLLTEFNKSTDAYELKIANKLFGEKTYLFLQEYLDAIKKFY QTSESVDFANAPEESRKKINSWVESQTNEKIKNLIPEGNIGSNTTLVLNA IYFKGQWEKKFNKEDTKEEKFWPNKNTYKSIQMMRQYTSFHFASLEDVQA KVLEIPYKGKDLSMIVLLPNEIDGLQKLEEKLTAEKLMEWTSLQNMRETR VDLHLPRFKVEESYDLKDTLRTMGMVDIFNGDADLSGMTGSRGLVLSGVL HKAFVEVTEEGAEAAAATAVVGFGSSPTSTNEEFHCNHPFLFFIRQNKTN SILFYGRFSSP |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCCA1/SCCA2重组蛋白的3篇文献摘要(基于公开信息模拟整理，非真实文献)：
---
1. **文献名称**：*"Cloning and functional analysis of recombinant SCCA1/SCCA2 serpins: implications in protease inhibition and tumor biology"*
**作者**：Schick C. et al.
**摘要**：研究通过重组技术表达SCCA1和SCCA2蛋白，发现SCCA1抑制半胱氨酸蛋白酶(如cathepsin K)，而SCCA2抑制丝氨酸蛋白酶(如糜蛋白酶)。两者通过不同抑制机制参与肿瘤微环境调控。
2. **文献名称**：*"SCCA1/SCCA2 recombinant proteins as biomarkers in idiopathic pulmonary fibrosis"*
**作者**：Takeda K. et al.
**摘要**：利用重组SCCA1/SCCA2蛋白检测特发性肺纤维化患者血清水平，发现SCCA2显著升高并与疾病进展相关，提示其可能作为纤维化过程的生物标志物。
3. **文献名称**：*"Structural characterization of SCCA2 recombinant protein and its role in modulating NF-κB signaling"*
**作者**：Cataltepe S. et al.
**摘要**：通过X射线晶体学解析重组SCCA2蛋白结构，揭示其通过抑制IKK复合物活性阻断NF-κB通路，为抗炎及抗肿瘤治疗提供潜在靶点。
---
注：以上文献为模拟示例，实际研究需通过PubMed/Google Scholar等平台以关键词“SCCA1/SCCA2 recombinant protein”检索真实文献。
Squamous cell carcinoma antigen 1 (SCCA1) and SCCA2. encoded by the *SERPINB3* and *SERPINB4* genes, respectively, are members of the serine protease inhibitor (serpin) superfamily. Initially identified as tumor markers in squamous cell carcinomas, these proteins are characterized by their distinct inhibitory functions. SCCA1 primarily inhibits cysteine proteases, such as cathepsin K and papain, while SCCA2 targets serine proteases, including chymase and cathepsin G. Their differential protease inhibition reflects structural variations in their reactive center loops, which dictate substrate specificity. Both isoforms share ~92% amino acid sequence identity, yet their divergent roles highlight functional specialization within the serpin family.
Beyond oncology, SCCA1/SCCA2 are implicated in inflammatory and immune responses. Elevated expression is observed in chronic inflammatory conditions (e.g., asthma, psoriasis) and viral infections, suggesting roles in modulating host defense mechanisms. SCCA1. in particular, may protect epithelial tissues from protease-mediated damage during inflammation. Conversely, their overexpression in tumors correlates with metastasis and poor prognosis, potentially through protease inhibition pathways that favor tumor survival or immune evasion.
Recombinant SCCA1/SCCA2 proteins are produced via heterologous expression systems (e.g., *E. coli*, mammalian cells) for functional studies and therapeutic development. These recombinant variants retain native inhibitory activity and are used to investigate their roles in cancer biology, autoimmune disorders, and infection models. Recent studies explore their potential as diagnostic biomarkers or immunotherapeutic targets. For instance, SCCA1-based vaccines and monoclonal antibodies are under evaluation for cancer immunotherapy. However, challenges remain in elucidating their dual roles in tissue protection versus disease progression, necessitating further structural and mechanistic research to harness their clinical potential.
×
